908 Devices adds new drug targets to MX908, announces strong 2025
The US chemical detection and identification company has added new drug targets to its handheld MX908 mass spectrometry device for trace chemical identification.
"These enhancements include an updated mission mode for hazardous vapour sampling and the addition of five priority drug targets," a press release issued by the company on 5 February said.
The device’s "Hazard Survey" mode, which originally provided users with a broad but less detailed analysis, has been replaced with the TIC [toxic industrial chemical] Hunter. This is dedicated mission mode for focused hazardous vapour detection which "provides first responders with a more guided and purpose-built tool that delivers clearer, faster conclusions for real-world response scenarios", according to 908 Devices.
Furthermore, five drug targets have been added to the MX908, namely:
- Medetomidine - a non-opioid, veterinary sedative that is often mixed with fentanyl and is estimated to be 200 times more potent than xylazine, another veterinary sedative.
- Synthetic cathinone - N-isopropyl butylone, which has quickly emerged as the second most reported stimulant in the latter half of 2025 and is a Schedule I substance in the US.
- Two synthetic cannabinoids: ADB-PINACA, a Schedule I substance, and MDMB-BINACA, which has been observed in the US, Canada, UK, Europe and Asia.
- Benzodiazepine: Bromazolam, which is frequently found mixed with other drugs, including fentanyl.
"These latest enhancements reinforce MX908’s unmatched capability for rapid trace chemical identification at the point of need," said Trey Sieger, senior director of product management at 908 Devices. "By delivering fast, reliable results, MX908 equips law enforcement officers, military personnel, and hazmat teams with actionable intelligence they can trust to make critical decisions when every second counts."
Customers can add these new capabilities to their MX908 device through a software update, available via the 908 Devices Customer Support Portal.
908 Devices reports strong Q4 and 2025 preliminary results
The update to the company's MX908 device follows strong preliminary financial results for Q4 and the full year of 2025.
"Preliminary unaudited revenue for the fourth quarter of 2025 is approximately $17.2 million USD, compared to $14.3 million in the fourth quarter of 2024, reflecting reported growth of approximately 20 percent," a press release issued on 20 January said. "Fourth quarter strength was driven by continued overperformance within the US state and local channel, ramping adoption of VipIR internationally, and sales to federal and defence customers."
"Preliminary unaudited revenue for the year ended December 31, 2025 is expected to be approximately $56.0 million, compared to audited revenue of $47.7 million in full year 2024, reflecting reported growth of approximately 17% and aligning with the high end of revenue guidance."
CEO and co-founder, Kevin J. Knopp, said: “In 2025, we transformed our company into a stronger, simpler, and more profitable financial model focused on frontline chemical detection."
"We achieved strong top-line growth and our goal to be Adjusted EBITDA positive in the fourth quarter. These solid results and powerful macro trends, including increased funding to combat the fentanyl and opioid crisis and increased global defence budgets, position us well for future growth."
